Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
BioLife Solutions (BLFS)
#1
Quote:B. Riley FBR resumes BioLife Solutions at Buy with $27 price target B. Riley FBR analyst Marc Wiesenberger resumed coverage of BioLife Solutions with a Buy rating and $27 price target, stating that as cell and gene therapies gain approval he sees BioLife's revenues as likely to scale "commensurately" given that its unique preservation technology is being used extensively in the associated clinical trials. The FDA expects to be approving 10-20 cell and gene therapy drugs every year by 2025, noted Wiesenberger, who sees BioLife taking increased wallet share from its "sticky" customer base.
 
B. Riley FBR resumes BioLife Solutions at Buy with $27 price target BLFS - The Fly
Reply



Forum Jump:


Users browsing this thread: 1 Guest(s)